FDA Shifts Away From Advisory Panel Meetings; Transparency Worries Grow

FDA Shifts Away From Advisory Panel Meetings; Transparency Worries Grow Industry leaders and academics are concerned that decision-making input from agency leaders, drug developers, patients, and physicians has largely been cast aside during the Trump administration. Plus, Democrats are going to drugmakers directly for information about Trump's drug deals. https://kffhealthnews.org/morning-breakout/fda-shifts-away-from-advisory-panel-meetings-transparency-worries-grow/